Inactive Instrument

News Ampliphi Biosciences Corp Nyse

Equities

APHB

US03211P2020

Biotechnology & Medical Research

Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	Nov. 12	CI
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update	Nov. 12	PR
Armata Pharmaceuticals Announces Formal Commissioning of Cgmp Phage Manufacturing Facility in Los Angeles, California	Nov. 10	CI
Armata Pharmaceuticals Commissions Manufacturing Facility in Los Angeles	Nov. 10	MT
Armata Pharmaceuticals commissions cGMP manufacturing facility in Los Angeles	Nov. 10	RE
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California	Nov. 10	PR
Health Rounds: Viruses may hold key to tackling deadly bacterial infection	Oct. 31	RE
Could the Next Breakthrough in Antibiotic Resistance Come From Viruses That Kill Bacteria?	Oct. 28	AQ
Top Premarket Decliners	Oct. 23	MT
Top Midday Gainers	Oct. 22	MT
Armata Says Bacteriophage Therapy Shows Efficacy Against Bacteremia in Phase 2a Study	Oct. 22	MT
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus Aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025	Oct. 22	CI
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™	Oct. 22	PR
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™	Oct. 14	PR
Armata Pharmaceuticals to Present Late-Breaking Clinical Data Highlighting Its Staphylococcus Aureus Bacteriophage Cocktail, Ap-Sa02, At Idweek 2025	Oct. 14	CI
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology	Sep. 08	PR
Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference	Sep. 04	PR
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update	Aug. 12	PR
Armata Pharmaceuticals, Inc. Enter into Secured Credit Agreement with Innoviva Strategic Opportunities LLC	Aug. 12	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	Aug. 12	CI
HC Wainwright Adjusts Armata Pharmaceuticals Price Target to $9 From $7, Maintains Buy Rating	May. 19	MT
Armata Pharmaceuticals, Inc. Announces Positive Topline Data from the Phase 1B/2A diSArm Study of Intravenous Administration AP-SA02 in Complicated Staphylococcus Aureus Bacteremia	May. 19	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 14	CI
Innoviva Reports First Quarter 2025 Financial Results, Highlights Recent Company Progress	May. 08	AQ
Armata Pharmaceuticals : 2025 Annual Meeting Proxy	Apr. 29	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Ampliphi Biosciences Corp Nyse

Equities

APHB

US03211P2020

Biotechnology & Medical Research

Filters